Novel antiplatelet agents in acute coronary syndrome

摘要: For more than 10 years, dual antiplatelet therapy with aspirin and clopidogrel has remained the cornerstone of treatment for patients acute coronary syndrome (ACS). The novel oral P2Y purinoceptor 12 (P2Y12)-receptor inhibitors prasugrel ticagrelor were approved by FDA clinical use in 2009 2011, respectively. These agents have a faster-acting, more-potent, more-predictable effect clopidogrel, which translates into improved outcomes ACS, albeit at expense an increased risk bleeding. However, some continue to experience adverse ischaemic events despite P2Y12-receptor antagonist, because platelets can remain activated via pathways not inhibited these agents, such as protease-activated receptor (PAR)-1 platelet activation pathway stimulated thrombin. Emerging therapies that might address limitations include intravenous P2Y12 antagonists, PAR-1 thromboxane-receptor inhibitors. In this Review, we provide overview drugs, including newly emerging compounds currently under development, also discuss evolving concepts unmet needs related ACS.